Q-omics provides the consensus-scored OFD1P17 profile across patient tissues and cancer cell-line models. OFD1P17 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, OFD1P17 is differentially expressed in 8, with the highest sampling consensus in BLCA. Additionally, OFD1P17 RNA expression shows 14,830 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight LIHC, BLCA, and LAML as cancer lineages where OFD1P17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OFD1P17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OFD1P17 survival associations across molecular data types. OFD1P17 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OFD1P17 RNA expression–survival associations across cancer types. High OFD1P17 expression shows unfavorable associations in LIHC and KIRC, but favorable associations in COAD, READ, UVM and CESC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for OFD1P17 RNA expression.
This table summarizes OFD1P17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for OFD1P17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OFD1P17 shows lower tumor expression in KIRP and ESCA and higher tumor expression in BLCA, LUSC, HNSC and COAD. The BLCA box plot shows higher OFD1P17 RNA expression in tumor versus normal tissue (log2 FC = +0.059, t-test p = .008).
This table shows molecular features associated with OFD1P17 in patient tissues and cancer cell lines. In patient samples, OFD1P17 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
